Abstract BACKGROUND In Crohn’s disease (CD), 10% to 40% of patients do not respond to anti-tumor necrosis factor-α (TNFα) treatment. Currently, there are no biomarkers with adequate sensitivity to separate responders from nonresponders at an early stage. AIM The aim of this study was to investigated whether early changes in the VICM (citrullinated and matrix […]
The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn’s Disease.
January 1, 2021
J Clin Gastroenterol